Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21152683 | 0.85 | WNT3A (0.58) | WNT3AABL1SMN1; SMN2 | |
| SCHEMBL16238156 | 0.83 | NPC1 (0.61) | WNT3AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL19376901 | 0.81 | WNT3A (0.44) | WNT3ATDP1 | |
| SCHEMBL22975368 | 0.80 | PTK2 (0.56) | WNT3AABL1 | |
| SCHEMBL17673081 | 0.79 | PORCN (0.60) | WNT3A | |
| SCHEMBL29883158 | 0.76 | TDP1 (0.71) | TDP1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL2188598 | 0.76 | TDP1 (0.71) | TDP1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL1428235 | 0.74 | L3MBTL1 (0.48) | TDP1KDM4EALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL1503943 | 0.74 | TDP1 (0.69) | TDP1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL30440538 | 0.74 | RAB9A (0.66) | KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | REDX PHARMA PLC (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| EP-3204378-B3 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-3204378-B3 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10202375-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | REDX PHARMA PLC (GB) | 2019-02-12 | — | — | US | disclosed |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20170298062-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| EP-3204378-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Redx Pharma PLC (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055786-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055790-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055786-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202375-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | WNT1, WNT3, CTNNB1 | WNT3A 6/4885TDP1 4824/4885ABL1 1590/4885 |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | WNT1, WNT3, CTNNB1 | WNT3A 6/4885TDP1 4680/4885ABL1 1283/4885 |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | WNT3A 6/4885TDP1 4680/4885ABL1 1283/4885 |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | WNT3A 6/4885TDP1 4806/4885ABL1 1829/4885 |
| US-20170298062-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | WNT1, WNT3, CTNNB1 | WNT3A 6/4885TDP1 4824/4885ABL1 1590/4885 |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | WNT3A 6/4885TDP1 4806/4885ABL1 1829/4885 |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | WNT3A 6/4885TDP1 4680/4885ABL1 1283/4885 |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | WNT3A 6/4885TDP1 4680/4885ABL1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.